Cargando…

Bempegaldesleukin (BEMPEG; NKTR‐214) efficacy as a single agent and in combination with checkpoint‐inhibitor therapy in mouse models of osteosarcoma

Survival of patients with relapsed/refractory osteosarcoma has not improved in the last 30 years. Several immunotherapeutic approaches have shown benefit in murine osteosarcoma models, including the anti‐programmed death‐1 (anti‐PD‐1) and anti‐cytotoxic T‐lymphocyte antigen‐4 (anti‐CTLA‐4) immune ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hennessy, Marlene, Wahba, Andrew, Felix, Kumar, Cabrera, Mariella, Segura, Maria Gabriela, Kundra, Vikas, Ravoori, Murali K., Stewart, John, Kleinerman, Eugenie S., Jensen, Vanessa Behrana, Gopalakrishnan, Vidya, Pena, Rhoneil, Quach, Phi, Kim, Grace, Kivimäe, Saul, Madakamutil, Loui, Overwijk, Willem W., Zalevsky, Jonathan, Gordon, Nancy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Cancer Therapy and Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984260/ https://www.ncbi.nlm.nih.gov/pubmed/33152115 http://dx.doi.org/10.1002/ijc.33382

Ejemplares similares

Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8(+) T cell cytotoxicity over BEMPEG+RT
por: Rolig, Annah S, et al.
Publicado: (2022)

NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy
por: Miyazaki, Takahiro, et al.
Publicado: (2021)

Synergistic antitumor activity of the CD122-biased immunostimulatory cytokine NKTR-214 when combined with anti-PD-1 in murine tumor models
por: Murali, Addepalli, et al.
Publicado: (2015)

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
por: Charych, Deborah, et al.
Publicado: (2017)

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
por: Diab, Adi, et al.
Publicado: (2021)

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
por: Sharma, Meenu, et al.
Publicado: (2020)

NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8(+) T cell responses capable of curing multi-focal cancer
por: Walker, Joshua M, et al.
Publicado: (2020)

Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice
por: Pieper, Alexander A, et al.
Publicado: (2021)

Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab
por: Veatch, Joshua R, et al.
Publicado: (2020)

Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
por: D’Angelo, Sandra P., et al.
Publicado: (2022)

Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus
por: Fanton, Christie, et al.
Publicado: (2022)

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
por: Tannir, Nizar M, et al.
Publicado: (2022)

Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15
por: Fernandez, Rafael Alonso, et al.
Publicado: (2022)

In vivo and in vitro Characterization of a Partial Mu Opioid Receptor Agonist, NKTR-181, Supports Future Therapeutic Development
por: Lee, Alex S., et al.
Publicado: (2021)

Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone
por: Webster, Lynn, et al.
Publicado: (2018)

Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report
por: Anastasopoulou, Amalia, et al.
Publicado: (2022)

NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases
por: Dixit, Neha, et al.
Publicado: (2021)

NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer
por: Adkins, Chris E., et al.
Publicado: (2015)

Gene expression profile of human colorectal cancer identified NKTR as a biomarker for liver metastasis
por: Bai, Rui, et al.
Publicado: (2022)

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results
por: Diab, Adi, et al.
Publicado: (2023)

Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial
por: Feils, A. S., et al.
Publicado: (2023)

ACT001 inhibits the proliferation of non‐small cell lung cancer cells by upregulating NKTR expression
por: Zhao, Min, et al.
Publicado: (2022)

Role of Vγ9vδ2 T lymphocytes in infectious diseases
por: Gay, Laetitia, et al.
Publicado: (2022)

Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia
por: Luyt, Charles-Edouard, et al.
Publicado: (2009)

NKTR-061 (inhaled amikacin) delivers high lung doses in mechanically ventilated patients with pneumonia and in healthy subjects
por: Eldon, M, et al.
Publicado: (2008)

High epithelial lining fluid concentrations of NKTR-061 (inhaled amikacin) twice daily achieved in pneumonic portions of lung
por: Chastre, J, et al.
Publicado: (2008)

Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma
por: Nagpal, Seema, et al.
Publicado: (2015)

Tumor Vessel Development and Expansion in Ewing's Sarcoma: A Review of the Vasculogenesis Process and Clinical Trials with Vascular-Targeting Agents
por: Stewart, Keri S., et al.
Publicado: (2011)

Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models
por: Hoch, Ute, et al.
Publicado: (2014)

Epigenetic Regulation of Apoptosis and Cell Cycle in Osteosarcoma
por: Rao-Bindal, Krithi, et al.
Publicado: (2011)

Combination of Bempegaldesleukin and Anti-CTLA-4 Prevents Metastatic Dissemination After Primary Resection or Radiotherapy in a Preclinical Model of Non-Small Cell Lung Cancer
por: Bates, Amber M., et al.
Publicado: (2021)

BTN3A Targeting Vγ9Vδ2 T Cells Antimicrobial Activity Against Coxiella burnetii-Infected Cells
por: Gay, Laetitia, et al.
Publicado: (2022)

New Dual Mode Gadolinium Nanoparticle Contrast Agent for Magnetic Resonance Imaging
por: Ghaghada, Ketan B., et al.
Publicado: (2009)

Combination of NK cells therapy and oral administration of entinostat as an approach for osteosarcoma lung metastasis treatment
por: Kiany, Simin, et al.
Publicado: (2015)

Exercise intervention decreases acute and late doxorubicin‐induced cardiotoxicity
por: Wang, Fei, et al.
Publicado: (2021)

The Innate Immune System in Cardiovascular Diseases and Its Role in Doxorubicin-Induced Cardiotoxicity
por: Bhagat, Anchit, et al.
Publicado: (2022)

Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions
por: Wolf-Dennen, Kerri, et al.
Publicado: (2020)

Health Tract, No. 214: Potatoes
Publicado: (1864)

Health Tract, No. 214: Potatoes
Publicado: (1865)

Clinics in diagnostic imaging (214)
por: Li, Junsiyuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uie8krv1cftus00cm5jhjvum87